within Pharmacolibrary.Drugs.ATC.N;

model N06BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06BX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pyritinol is a semi-synthetic derivative of vitamin B6 (pyridoxine) that has been used as a nootropic and cognitive enhancer in the treatment of cognitive disorders, such as dementia or learning disabilities. It is not approved in all countries and is considered obsolete in many jurisdictions but is still available as a prescription medicine in some European countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical healthy adults based on available literature summaries and indirect sources, as no precise PK population models or detailed compartmental data were found.</p><h4>References</h4><ol><li><p>Freundt, KJ, et al., &amp; Voigt, HO (1984). Concentrations of D-glucaric acid in human urine after repeated administration of pyrithioxine. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 22(12) 639–642. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6526537/&quot;>https://pubmed.ncbi.nlm.nih.gov/6526537</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06BX02;
